ReviewJournal of diabetes and metabolic disorders2025
MicroRNAs in diabetes mellitus.
Review in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is one of the most common chronic diseases, with a global distribution. Its prevalence is constantly increasing, along with the rising incidence of diabetes-related complications such as diabetic nephropathy, neuropathy, and retinopathy. MicroRNAs are endogenous, non-coding RNAs that regulate gene expression at the post-transcriptional level. Evidence suggests that altered microRNA expression has been implicated in various human disorders, including diabetes mellitus. Dysregulated expression of microRNAs leads to insulin resistance, causing diabetes mellitus and its associated complications. Moreover, other non-coding RNAs, such as long non-coding RNAs and circular RNAs, along with epigenetic factors and altered gut microbiota, contribute to disease development. Because of the stability of non-coding RNAs in circulation, they have the potential to be used as biomarkers for diagnosis and therapeutic implications. Evidence suggests that a myriad of factors are involved; hence, a collective approach involving non-coding RNAs, epigenetic factors, and gut microbiota could provide the best clinical outcomes for diabetes patients. Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-025-01591-y.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.